Plavix Pharmacogenomic Label Update May Help Lilly With Effient Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol/Sanofi blockbuster label was quietly updated two months ago to include precautionary statement and pharmacogenomic data about non-responders to Plavix. That label dovetails with Lilly's initial positioning of prasugrel.